ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学術雑誌論文
  2. 各雑誌掲載論文

Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study

http://hdl.handle.net/10271/00003888
http://hdl.handle.net/10271/00003888
37afe22f-a4d7-4677-b277-4970a0d8b5f8
名前 / ファイル ライセンス アクション
JTO-15-1317.pdf JTO-15-1317.pdf (1.8 MB)
license.icon
Item type 学術雑誌論文 / Journal Article(1)
公開日 2021-09-01
タイトル
タイトル Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study
言語 en
言語
言語 eng
キーワード
主題 Immune checkpoint inhibitor
キーワード
主題 Programmed death 1 (PD-1)
キーワード
主題 Non-small cell lung cancer (NSCLC)
キーワード
主題 immune-related interstitial lung disease
キーワード
主題 spirometry
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
その他のタイトル
その他のタイトル Impaired spirometry predicts ir-ILD
著者 Suzuki, Yuzo

× Suzuki, Yuzo

Suzuki, Yuzo

Search repository
Karayama, Masato

× Karayama, Masato

Karayama, Masato

Search repository
Uto, Tomohiro

× Uto, Tomohiro

Uto, Tomohiro

Search repository
Fujii, Masato

× Fujii, Masato

Fujii, Masato

Search repository
Matsui, Takashi

× Matsui, Takashi

Matsui, Takashi

Search repository
Asada, Kazuhiro

× Asada, Kazuhiro

Asada, Kazuhiro

Search repository
Kusagaya, Hideki

× Kusagaya, Hideki

Kusagaya, Hideki

Search repository
Kato, Masato

× Kato, Masato

Kato, Masato

Search repository
Matsuda, Hiroyuki

× Matsuda, Hiroyuki

Matsuda, Hiroyuki

Search repository
Matsuura, Shun

× Matsuura, Shun

Matsuura, Shun

Search repository
Toyoshima, Mikio

× Toyoshima, Mikio

Toyoshima, Mikio

Search repository
Mori, Kazutaka

× Mori, Kazutaka

Mori, Kazutaka

Search repository
Ito, Yasuhiro

× Ito, Yasuhiro

Ito, Yasuhiro

Search repository
Koyauchi, Takafumi

× Koyauchi, Takafumi

Koyauchi, Takafumi

Search repository
Yasui, Hideki

× Yasui, Hideki

Yasui, Hideki

Search repository
Hozumi, Hironao

× Hozumi, Hironao

Hozumi, Hironao

Search repository
Furuhashi, Kazuki

× Furuhashi, Kazuki

Furuhashi, Kazuki

Search repository
Enomoto, Noriyuki

× Enomoto, Noriyuki

Enomoto, Noriyuki

Search repository
Fujisawa, Tomoyuki

× Fujisawa, Tomoyuki

Fujisawa, Tomoyuki

Search repository
Nakamura, Yutaro

× Nakamura, Yutaro

Nakamura, Yutaro

Search repository
Inui, Naoki

× Inui, Naoki

Inui, Naoki

Search repository
Suda, Takafumi

× Suda, Takafumi

Suda, Takafumi

Search repository
書誌情報 Journal of thoracic oncology

巻 15, 号 8, p. 1317-1327, 発行日 2020-08
出版者
出版者 Elsevier
権利
権利情報 Copyright 2020 Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
権利
権利情報 "This is the accepted manuscript version. The formal published version is available at ""https://doi.org/10.1016/j.jtho.2020.04.002""."
抄録
内容記述タイプ Abstract
内容記述 Introduction: Programmed death-1 immune checkpoint inhibitors (ICIs) have been shown to improve survival of non-small cell lung cancer (NSCLC) patients. Upon expansion of clinical administration for a variety of cancers, immure-related adverse events (ir-AEs) have been typically recognized to be associated with ICIs therefore, necessitating the monitoring and management of these patients. Among ir-AEs, immune-related interstitial lung disease (ir-ILD) is a serious complication which interrupts treatment and occasionally, is fatal. However, no prospective studies have investigated incidences of ir-ILD and associated risk factors for its development in the clinical setting.
Methods: This was a prospective cohort study consisting of NSCLC patients treated with ICIs. Baseline characteristics, including laboratory data, pulmonary function tests (PFTs), daily dyspnea defined by the modified Medical Research Council (mMRC), and anti-tumor response were assessed.
Results: Among the 138 NSCLC patients that received anti-PD-1 monotherapy, 20 patients (14.5%) developed ir-ILD within median 51.5 days [29-147: interquartile]. This was approximately three-times higher than those in clinical trials. Eleven patients (55.0%), including all of eight patients with high-grade ir-ILD (?Grade 3), developed ir-ILD within 60 days. Impaired spirometry, decreased forced vital capacity (%FVC) and forced expiratory volume in 1.0 second (%FEV1), and daily dyspnea measured by mMRC were identified as risk factors for ir-ILD development. Additionally, combination assessment of %FVC and %FEV1 successfully classified patients at risk for ir-ILD development.
Conclusion: The incidences of ir-ILD were substantially higher in clinical setting. Assessment of spirometry and daily dyspnea before ICI treatment may be useful to monitor and manage NSCLC patients.
ISSN
収録物識別子タイプ ISSN
収録物識別子 1556-0864
EISSN
収録物識別子タイプ ISSN
収録物識別子 1556-1380
PubMed番号
関連タイプ isVersionOf
識別子タイプ PMID
関連識別子 32289515
出版社DOI
関連タイプ isVersionOf
識別子タイプ DOI
関連識別子 10.1016/j.jtho.2020.04.002
著者版フラグ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 16:25:35.594971
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3